Form 4: Forte Biosciences Director Receives Stock Units

Forte Biosciences, Inc. director David W. Gryska was granted 18,353 restricted stock units, vesting on the first annual meeting after May 29, 2026.

Summary

• David W. Gryska, a director at Forte Biosciences, Inc., was granted 18,353 restricted stock units (RSUs) on May 29, 2026.
• These RSUs represent a contingent right to receive one share of Forte Biosciences common stock per unit.
• The vesting of these RSUs is contingent upon Mr. Gryska remaining a Service Provider through the date of the first annual stockholders' meeting occurring after May 29, 2026.
• Following the reported transaction, Mr. Gryska beneficially owns 18,353 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard equity grant to a director rather than a significant financial event or strategic shift.

Positives

• Director David W. Gryska has been granted equity in the company, aligning his interests with shareholders.
• The grant of 18,353 RSUs indicates a commitment to retaining key leadership personnel.

Risks

• The vesting of the RSUs is contingent on Mr. Gryska's continued service, meaning forfeiture is possible if he departs before the vesting date.
• The value of the RSUs is tied to the future performance of Forte Biosciences' common stock.

Future Outlook

The vesting of the restricted stock units is scheduled for the first annual stockholders' meeting after May 29, 2026, provided the reporting person remains a service provider.

Industry Context

StockSavvy.ai notes that grants of restricted stock units to directors are a common practice in the biotechnology sector to incentivize long-term commitment and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns management's interests with shareholders, potentially leading to decisions that enhance long-term stock value.
• Employees: This filing does not directly impact employees, but it reflects standard compensation practices for directors.

Next Steps

• Vesting of 18,353 RSUs on the first annual stockholders' meeting after May 29, 2026, contingent on continued service.

Key Dates

Keywords

Forte Biosciences, FBRX, Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Incentive Plan, Beneficial Ownership, Vesting Schedule